The data reveal payments made for research, gifts, speaking fees, meals and travel.
South San Francisco-based Genentech, now a subsidiary of Roche, disclosed $295.4 million in general payments made in 2014, almost four times as much as AstraZeneca, the company with the next highest tally. The majority of that sum—$254.9 million—reflects royalty payments made to City of Hope, the California comprehensive cancer center that holds the patents on research underlying Genentech’s biggest drugs, Avastin, Rituxan and Herceptin.
Genentech also noted in a statement that it paid one physician $2.8 million and another $10.1 million to fulfill agreements they had with Seragon, a company Genentech acquired last year.
The median amount from all companies paid to physicians in 2014 was $233,376, and 125 companies paid more than $1 million. All told, the top 10 companies paid $709 million.